Braveheart launches with $185M to advance heart drug rivaling Bristol Myers’ therapy

Delaware, November 5, 2025 (finance yahoo) -- Braveheart Bio has emerged from stealth with $185 million in Series A funding to advance BHB-1893, a potential best-in-class treatment for hypertrophic cardiomyopathy licensed from China’s Hengrui Pharma. The company plans to launch global late-stage trials in 2026. Led by former HI-Bio CEO Travis Murdoch and chaired by Biogen’s Chris Viehbacher, Braveheart joins a growing wave of biotech startups licensing late-stage drugs from Chinese firms, signaling continued investor enthusiasm for cross-border innovation in cardiovascular medicine.

Read full article here.